Will Merck & Co (MRK) beat quarterly earnings?: how this market works

What you need to know

This market asks whether Merck & Co will report better-than-expected earnings per share when it releases quarterly results around August 4, 2026. The benchmark here is unusual: analysts currently expect Merck to report a loss of $0.25 per share, so "beating" means reporting any loss smaller than that, breaking even, or turning a profit. A Yes means Merck did better than Wall Street expected. A No means it met or missed that already-negative forecast. The market settles Yes if Merck's official non-GAAP earnings per share, the adjusted profit figure the company highlights in its earnings release, comes in above negative $0.25. The number used is whatever Merck reports on or around August 4, 2026, rounded to the nearest cent. If Merck delays more than 45 days past that date without reporting, it resolves No automatically. One important edge case: if Merck does not publish a non-GAAP figure, the market falls back to GAAP earnings instead. No relevant recent news was provided for this market. The kinds of updates worth watching for would include any changes to analyst earnings estimates for Merck, news about its key drug sales (especially Keytruda, its top cancer medicine), updates on patent challenges, or any company guidance that signals how the quarter is tracking. The market prices this at around 79% Yes, which reflects a strong lean but not a certainty. The main sources of uncertainty are real: a negative EPS target is already a low bar, which helps Yes, but pharmaceutical earnings can shift quickly due to legal settlements, one-time charges, or unexpected drug performance. The estimate itself, negative $0.25, suggests analysts already expect a difficult quarter, possibly from known headwinds. Whether the actual result clears even that low bar is what remains genuinely open.

The odds right now

• Will Merck & Co (MRK) beat quarterly earnings?80%

Price history

How this resolves

Resolves August 4, 2026

As of market creation, Merck & Co is estimated to release earnings on August 4, 2026. The Street consensus estimate for Merck & Co’s non-GAAP EPS for the relevant quarter is $-0.25 as of market creation. Read the full resolution rules on the live market page.

Related

Same markets. A fraction of the fee.

These apps all route to the same exchange order book. The difference is what each one adds on top of the exchange's own fee.

Published rates, checked July 2026. MetaMask charges a flat 4 percent per prediction trade. Jupiter adds a fee equal to the exchange's own taker fee at fill time, roughly 2 to 4 percent at typical odds. Where a market carries an exchange settlement fee, it applies everywhere, whichever app you use. Paridesk adds nothing on maker orders.

Trade this market on Paridesk: non-custodial, 0.5% fee.